- Home
- PCVX
PCVX
Vaxcyte Inc.
as of 12-05-2025 3:44pm EST
$46.76
+$0.69
+1.49%
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Chart Type:
Time Range:
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 6.0B | IPO Year: | 2020 |
| Target Price: | $101.67 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.66 - $94.60 | Next Earning Date: | 11-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered PCVX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 78.85%
78.85%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Vaxcyte Inc. News
PCVX Breaking Stock News: Dive into PCVX Ticker-Specific Updates for Smart Investing
Investor's Business Daily
Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10
MT Newswires
Top Premarket Decliners
Compare PCVX vs Leading Stocks
See how PCVX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PCVX Vaxcyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.